fda compounding semaglutide crackdown news november 2025 New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our The FDA has received reports

Ultrasmall Au nanoclusters for bioanalytical and biomedical applications: the undisclosed and neglected roles of ligands in determining the nanoclusters catalytic activities

10.1182/blood.v61.5.899.bloodjournal615899 12 CostaR

Amazing to see this kind of coordinated bet on turning research into real outcomes for patients

A large real-world analysis from Cleveland Clinic is now adding a different chapter

However, these medications profoundly shift metabolic biomarkers within weeks, including fasting glucose, HbA1c, insulin levels, and lipid profiles, which should be monitored regularly to assess efficacy and safety